ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1227

Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data
Abstract Number: 1228

Predicting RA Remission with Subcutaneous Abatacept Treatment in the Real-world Setting
Abstract Number: 1229

Does BMI Influence the Efficacy of Subcutaneous or Intravenous Abatacept in Patients with RA in Routine Clinical Practice? A Post Hoc Analysis of Two Real-world Observational Studies
Abstract Number: 1230

Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study
Abstract Number: 1231

Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
Abstract Number: 1232

Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients
Abstract Number: 1233

Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Abstract Number: 1234

Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy
Abstract Number: 1235

Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials
Abstract Number: 1236

Pain in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints with Baricitinib Clinical Trials
Abstract Number: 1237

Predictors of Response: Baseline Characteristics and Early Treatment Responses Associated with Achievement of Remission and Low Disease Activity Among Upadacitinib-Treated Patients with Rheumatoid Arthritis
Abstract Number: 1238

Low Patient Global Assessment of Disease Activity and Negative Rheumatoid Factor Are Strongly Associated with Likelihood of Maintaining Remission Following Tapering of Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 1239

Differences in Patient-Reported Outcomes Between Those Who Stay in Remission and Those Who Have Disease-Worsening Following Therapy Withdrawal in Patients with Rheumatoid Arthritis
Abstract Number: 1240

Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
Abstract Number: 1241

Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].